See how GLP-1 drugs reduce heart and kidney complications in MGUS and diabetes—explore the clinical evidence. Keep reading!

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

There are consistent associations between elevated urinary metal levels and increased HF risk over time across geographically diverse cohorts of adults.

Bayer presents Kerendia data in heart failure with preserved and mildly reduced LVEF at ESC, sparking debate about how it may fit into treatment.

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

BACKGROUND: Fontan circulatory failure (FCF) is a chronic state in palliated single ventricle heart disease with high morbidity and mortality rates, including heart failure, multisystem end-organ ...

Heart failure, a leading cause of death in the US, can be triggered by cardiac amyloidosis, a condition often misdiagnosed as hypertension or age-related issues. A cardiologist highlights that ...

A research team led by Prof. Liu Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Science has ...

Learn which heart problems can affect children, including congenital heart disease, arrhythmias, pericarditis, and Kawasaki disease. Learn about signs and treatment.

Read current medical research on risk factors, causes and prevention of heart disease, strokes, and peripheral arterial disease. What new treatment options are under development?

This review addresses open questions about the role of β-adrenergic receptors in cardiac function and failure. Cardiomyocytes express all three β-adrenergic receptor subtypes—β1, β2, and, at least in ...